Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats

Archives of Pharmacal Research - Tập 34 - Trang 1939-1943 - 2011
Yan Zhou1, Xin’an Wu1, Xiaohua Ma1,2, Yuhui Wei1, Li Ma1,2
1Department of Pharmacy, 1st Hospital of Lanzhou University, Lanzhou, China
2College of Pharmacy, Lanzhou University, Lanzhou, China

Tóm tắt

The aim of this study was to investigate the effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin. Intestinal permeability of rifampicin with or without excipients was evaluated by an in situ single-pass perfusion method. A highperformance liquid chromatographic method was applied to study the pharmacokinetics of rifampicin with or without excipients. Labrasol or Pluronic F68 (0.1% and 0.05%, v/v), co-perfused with rifampicin (60 μg/mL), significantly increased in situ permeability. Similarly, verapamil (a typical P-gp inhibitor) also increased in situ permeability, but to a lesser extent. In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t1/2 (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg). In addition, Pluronic F68, Labrasol and verapamil produced minor changes in AUC0−t, which improved 1.55-, 1.54-, and 1.73-fold in comparison to control group, respectively. These results showed that Labrasol and Pluronic F68 might inhibit the function of P-gp in the intestine, thereby increasing intestinal absorption and changing the pharmacokinetic parameters of rifampicin. Therefore, excipient selection is an important factor to consider in rational formulation design.

Tài liệu tham khảo

Bansal, T., Mishra, G., Jaggi, M., Khar, R. K., and Talegaonkar, S., Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur. J. Pharm. Sci., 36, 580–590 (2009).

Burman, W. J., Gallicano, K., and Peloquin, C., Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet., 40, 327–341 (2001).

Hu, Z., Tawa, R., Konishi, T., Shibata, N., and Takada, K., A novel emulsifier, labrasol, enhances gastrointestinal absorption of gentamicin. Life Sci., 69, 2899–2910 (2001).

Huang, J., Si, L., Jiang, L., Fan, Z., Qiu, J., and Li, G., Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int. J. Pharm., 356, 351–353 (2008).

Issa, C., Gupta, P., and Bansal, A. K., Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: a technical note. AAPS PharmSciTech, 4, E16 (2003).

Jain, R., Duvvuri, S., Kansara, V., Mandava, N. K., and Mitra, A. K., Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int. J. Pharm., 336, 233–240 (2007).

Koup, J. R., Williams-Warren, J., Viswanathan, C. T., Weber, A., and Smith, A. L., Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther. Drug Monit., 8, 17–22 (1986).

Lin, Y., Shen, Q., Katsumi, H., Okada, N., Fujita, T., Jiang, X., and Yamamoto, A., Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats. Biol. Pharm. Bull., 30, 1301–1307 (2007).

Mariappan, T. T. and Singh, S., Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. Mol. Pharm., 1, 363–367 (2004).

Mitchison, D. A., The Garrod Lecture. Understanding the chemotherapy of tuberculosis-current problems. J. Antimicrob. Chemother., 29, 477–493 (1992).

Nerurkar, M. M., Ho, N. F., Burton, P. S., Vidmar, T. J., and Borchardt, R. T., Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci., 86, 813–821 (1997).

Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G. K., and Prasad, B., Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother., 52, 981–986 (2003).

Pargal, A. and Rani, S., Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int. J. Tuberc. Lung Dis., 5, 70–79 (2001).

Pillai, G., Fourie, P. B., Padayatchi, N., Onyebujoh, P. C., McIlleron, H., Smith, P. J., and Gabriels, G., Recent bioequivalence studies on fixed-dose combination antituberculosis drug formulations available on the global market. Int. J. Tuberc. Lung Dis., 3, S309–S316 (1999).

Rege, B. D., Kao, J. P., and Polli, J. E., Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci., 16, 237–246 (2002).

Schulze, J. D., Peters, E. E., Vickers, A. W., Staton, J. S., Coffin, M. D., Parsons, G. E., and Basit, A. W., Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int. J. Pharm., 300, 67–75 (2005).

Shishoo, C. J., Shah, S. A., Rathod, I. S., Savale, S. S., and Vora, M. J., Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int. J. Pharm., 228, 53–67 (2001).

Sutton, S. C., Rinaldi, M. T., and Vukovinsky, KE., Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat singlepass intestinal perfusion model. AAPS PharmSci., 3, E25 (2001).

Varma, M. V. and Panchagnula, R., Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci., 25, 445–453 (2005).

Thông tin
Thông tin xuất bản

Archives of Pharmacal Research

Tập 34

1939-1943

Thông tin tác giả